Ozkok S, Ozkok A. Contrast-induced acute kidney injury: a review of practical points. World J Nephrol. 2017;6(3):86–99.
Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. EUR HEART J. 2012;33(16):2007–15.
Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. NEPHRON. 2012;120(4):c179–84.
van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb J, et al. Post-contrast acute kidney injury – part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. EUR RADIOL. 2018;28(7):2845–55.
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. RADIOLOGY 2020, 294(3):660–668.
Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (part 2). CRIT CARE. 2013;17(1):205.
van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb J, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. EUR RADIOL. 2018;28(7):2856–69.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. NEW ENGL J MED. 2016;375(4):323–34.
Stratta P, Quaglia M, Airoldi A, Aime S. Structure-function relationships of iodinated contrast media and risk of nephrotoxicity. CURR MED CHEM. 2012;19(5):736–43.
Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated contrast agents. MAGN RESON IMAGING C. 2017;25(4):697–704.
Thomsen HS, Morcos SK. Prevention of generalized reactions to CM. ACAD RADIOL. 2002;9(Suppl 2):S433–5.
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almen T, Aspelin P, Bellin MF, Clement O, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. EUR RADIOL. 2011;21(12):2527–41.
Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). CRIT CARE. 2013;17(1):204.
Chen Y, Chen J, Fu G, Du Z, Fang Q, Cui L, et al. Chinese expert consensus on adverse reactions related to iodide contrast angiography. Chin J Intervention Cardiol. 2014;22(06):341–8.
Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616–43.
Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J AM COLL CARDIOL. 2004;44(9):1763–71.
Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. CARDIOVASC INTERV TH. 2020;35(3):209–17.
Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced Nephropathy: from pathophysiology to preventive strategies. CAN J CARDIOL. 2016;32(2):247–55.
Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JN, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. KIDNEY INT. 2012;81(5):477–85.
Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. EUR J RADIOL. 2013;82(9):e387–99.
Kooiman J, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, Dekkers OM. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. EUR J RADIOL. 2012;81(10):2554–61.
Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799–806.
Azzalini L. The clinical significance and management implications of chronic total occlusion Associated with Surgical Coronary Artery Revascularization. CAN J CARDIOL. 2016;32(11):1286–9.
Scharnweber T, Alhilali L, Fakhran S. Contrast-Induced Acute kidney Injury: pathophysiology, manifestations, Prevention, and management. MAGN RESON IMAGING C. 2017;25(4):743–53.
Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J TRANSL MED. 2020;18(1):400.
Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. INVEST RADIOL. 2010;45(4):188–95.
Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. AM J PHYSIOL-RENAL. 2001;280(1):F61–70.
McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute kidney Injury. J AM COLL CARDIOL. 2016;68(13):1465–73.
Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. KIDNEY INT. 2003;64(1):128–39.
Liu GL, Lei R, Duan SB, Tang MM, Luo M, Xu Q. Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells. EXP THER MED. 2017;14(4):3309–13.
Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. CLIN EXP PHARMACOL P. 2011;38(5):292–9.
Huang S, Tang Y, Liu T, Zhang N, Yang X, Yang D, Hong G. A novel antioxidant protects against contrast Medium-Induced Acute kidney Injury in rats. FRONT PHARMACOL. 2020;11:599577.
Ward DB, Brown KC, Valentovic MA. Radiocontrast Agent Diatrizoic Acid induces Mitophagy and oxidative stress via Calcium Dysregulation. INT J MOL SCI 2019, 20(17).
Hu C, Zhou G, Liu K, Yin W, Zhou L, Wang J, Chen L, Zuo S, Xie Y, Zuo X. CaMKII as a key regulator of contrast-induced nephropathy through mPTP opening in HK-2 cells. CELL SIGNAL. 2020;75:109734.
Caiazza A, Russo L, Sabbatini M, Russo D. Hemodynamic and tubular changes induced by contrast media. BIOMED RES INT 2014, 2014:578974.
Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. CLIN J AM SOC NEPHRO. 2008;3(1):288–96.
Dugbartey GJ, Redington AN. Prevention of contrast-induced nephropathy by limb ischemic preconditioning: underlying mechanisms and clinical effects. AM J PHYSIOL-RENAL. 2018;314(3):F319–28.
Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. INT J CARDIOL. 2012;158(2):186–92.
Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S. Early renal medullary hypoxic injury from radiocontrast and indomethacin. KIDNEY INT. 1991;40(4):632–42.
Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, Tsitsimpikou C, Tsatsakis A. Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies. PHARMACOL THERAPEUT. 2017;180:99–112.
Bucher AM, De Cecco CN, Schoepf UJ, Meinel FG, Krazinski AW, Spearman JV, McQuiston AD, Wang R, Bucher J, Vogl TJ, et al. Is contrast medium osmolality a causal factor for contrast-induced nephropathy? BIOMED RES INT. 2014;2014:931413.
Li Y, Ren K. The Mechanism of Contrast-Induced Acute Kidney Injury and Its Association with Diabetes Mellitus. CONTRAST MEDIA MOL I 2020, 2020:3295176.
Dai H, Zhao C, Xiong Y, He Q, Su W, Li J, Yang Y, Lin R, Xiang S, Shao J. Evaluation of contrast-induced acute kidney injury using IVIM and DKI MRI in a rat model of diabetic nephropathy. INSIGHTS IMAGING. 2022;13(1):110.
Pisani A, Riccio E, Andreucci M, Faga T, Ashour M, Di Nuzzi A, Mancini A, Sabbatini M. Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. BIOMED RES INT 2013, 2013:868321.
Said-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. BIOMED J. 2012;35(6):437–49.
Kanasaki K, Taduri G, Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. FRONT ENDOCRINOL. 2013;4:7.
Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. IMMUNOL REV. 2008;223:20–38.
Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. CLIN CANCER RES. 2013;19(9):2301–9.
Lee HC, Sheu SH, Yen HW, Lai WT, Chang JG. JNK/ATF2 pathway is involved in iodinated contrast media-induced apoptosis. AM J NEPHROL. 2010;31(2):125–33.
Ren Z, He H, Zuo Z, Xu Z, Wei Z, Deng J. The role of different SIRT1-mediated signaling pathways in toxic injury. CELL MOL BIOL LETT. 2019;24:36.
Hong YA, Bae SY, Ahn SY, Kim J, Kwon YJ, Jung WY, Ko GJ. Resveratrol ameliorates contrast Induced Nephropathy through the activation of SIRT1-PGC-1alpha-Foxo1 signaling in mice. KIDNEY BLOOD PRESS R. 2017;42(4):641–53.
Wirth A. Rho kinase and hypertension. Biochim Biophys Acta. 2010;1802(12):1276–84.
Zhang X, Ding M, Zhu P, Huang H, Zhuang Q, Shen J, Cai Y, Zhao M, He Q. New Insights into the Nrf-2/HO-1 Signaling Axis and Its Application in Pediatric Respiratory Diseases. OXID MED CELL LONGEV 2019, 2019:3214196.
Tongqiang L, Shaopeng L, Xiaofang Y, Nana S, Xialian X, Jiachang H, Ting Z, Xiaoqiang D. Salvianolic Acid B Prevents Iodinated Contrast Media-Induced Acute Renal Injury in Rats via the PI3K/Akt/Nrf2 Pathway. OXID MED CELL LONGEV 2016, 2016:7079487.
Goodman AI, Olszanecki R, Yang LM, Quan S, Li M, Omura S, Stec DE, Abraham NG. Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. KIDNEY INT. 2007;72(8):945–53.
Zhao Z, Liao G, Zhou Q, Lv D, Holthfer H, Zou H. Sulforaphane Attenuates Contrast-Induced Nephropathy in Rats via Nrf2/HO-1 Pathway. OXID MED CELL LONGEV 2016, 2016:9825623.
Keaney JJ, Hannon CM, Murray PT. Contrast-induced acute kidney injury: how much contrast is safe? NEPHROL DIAL TRANSPL. 2013;28(6):1376–83.
Liu ZZ, Schmerbach K, Lu Y, Perlewitz A, Nikitina T, Cantow K, Seeliger E, Persson PB, Patzak A, Liu R, et al. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback. AM J PHYSIOL-RENAL. 2014;306(8):F864–72.
Liu Y, Liu YH, Tan N, Chen JY, Zhou YL, Li LW, Duan CY, Chen PY, Luo JF, Li HL, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS ONE. 2014;9(10):e111124.
Pattharanitima P, Tasanarong A. Pharmacological strategies to prevent contrast-induced acute kidney injury. BIOMED RES INT 2014, 2014:236930.
Toruan M, Pranata R, Setianto BY, Haryana SM. The Role of MicroRNA in Contrast-Induced Nephropathy: A Scoping Review and Meta-Analysis. BIOMED RES INT 2020, 2020:4189621.
Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. CELL RES. 2018;28(1):9–21.
Ward DB, Valentovic MA. Contrast Induced Acute kidney Injury and direct cytotoxicity of Iodinated Radiocontrast Media on Renal Proximal Tubule cells. J PHARMACOL EXP THER. 2019;370(2):160–71.
Liu K, Hu C, Yin W, Zhou L, Gu X, Zuo X. An in vivo and in vitro model on the protective effect of cilnidipine on contrast-induced nephropathy via regulation of apoptosis and CaMKII/mPTP pathway. J BIOCHEM MOL TOXIC. 2023;37(1):e23238.
Komada T, Muruve DA. The role of inflammasomes in kidney disease. NAT REV NEPHROL. 2019;15(8):501–20.
Xiao S, Zhang J, Dong W, Jiang D, Yang K. Pyroptosis: a type of cell death associated with inflammation. Chem life. 2017;37(03):423–8.
Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. FRONT PHYSIOL. 2014;5:352.
Li N, Zhao T, Cao Y, Zhang H, Peng L, Wang Y, Zhou X, Wang Q, Li J, Yan M, et al. Tangshen Formula attenuates Diabetic kidney Injury by Imparting Anti-pyroptotic effects via the TXNIP-NLRP3-GSDMD Axis. FRONT PHARMACOL. 2020;11:623489.
Zhu X, Li S, Lin Q, Shao X, Wu J, Zhang W, Cai H, Zhou W, Jiang N, Zhang Z, et al. alphaKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy. PHARMACOL RES. 2021;167:105531.
Chen F, Lu J, Yang X, Xiao B, Chen H, Pei W, Jin Y, Wang M, Li Y, Zhang J et al. Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects. BIOSCIENCE REP 2020, 40(2).
Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS, Kayagaki N, Ciferri C, Dixit VM, Dueber EC. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. P NATL ACAD SCI USA. 2016;113(28):7858–63.
Zhang Z, Shao X, Jiang N, Mou S, Gu L, Li S, Lin Q, He Y, Zhang M, Zhou W, et al. Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury. CELL DEATH DIS. 2018;9(10):983.
Lin Q, Ni Z. Research progress of mitochondrial autophagy in kidney diseases. China Blood Purif. 2018;18(03):197–200.
Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. NAT REV NEPHROL. 2016;12(5):267–80.
Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J. 2008;27(2):306–14.
Lei R, Zhao F, Tang CY, Luo M, Yang SK, Cheng W, Li XW, Duan SB. Mitophagy plays a protective role in Iodinated contrast-Induced Acute Renal tubular epithelial cells Injury. Cell Physiol Biochem. 2018;46(3):975–85.
Cheng W, Zhao F, Tang CY, Li XW, Luo M, Duan SB. Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model. ARCH TOXICOL. 2018;92(7):2245–57.
Lin Q, Li S, Jiang N, Shao X, Zhang M, Jin H, Zhang Z, Shen J, Zhou Y, Zhou W, et al. PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation. REDOX BIOL. 2019;26:101254.
Yang X, Yan X, Yang D, Zhou J, Song J, Yang D. Rapamycin attenuates mitochondrial injury and renal tubular cell apoptosis in experimental contrast-induced acute kidney injury in rats. BIOSCIENCE REP 2018, 38(6).
Al-Shawadfy MG, Kamel G, Abd-Allah A. Crosstalk among apoptosis, inflammation, and autophagy in relation to melatonin protective effect against contrast-induced nephropathy in rats. CAN J PHYSIOL PHARM. 2022;100(9):858–67.
Ko GJ, Bae SY, Hong YA, Pyo HJ, Kwon YJ. Radiocontrast-induced nephropathy is attenuated by autophagy through regulation of apoptosis and inflammation. HUM EXP TOXICOL. 2016;35(7):724–36.
Dragomir MP, Knutsen E, Calin GA. SnapShot: unconventional miRNA functions. Cell. 2018;174(4):1038.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
Gutierrez-Escolano A, Santacruz-Vazquez E, Gomez-Perez F. Dysregulated microRNAs involved in contrast-induced acute kidney injury in rat and human. Ren Fail. 2015;37(9):1498–506.
Liu Y, Liu B, Liu Y, Chen S, Yang J, Liu J, Sun G, Bei WJ, Wang K, Chen Z, et al. MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury. ANN TRANSL MED. 2019;7(8):178.
Liu B, Chai Y, Guo W, Lin K, Chen S, Liu J, Sun G, Chen G, Song F, He Y, et al. MicroRNA-188 aggravates contrast-induced apoptosis by targeting SRSF7 in novel isotonic contrast-induced acute kidney injury rat models and renal tubular epithelial cells. ANN TRANSL MED. 2019;7(16):378.
Niu HM, Guo LQ, Qiao YH, Jiao HY. MiR-429 prohibited NF-kappaB signalling to alleviate contrast-induced acute kidney injury via targeting PDCD4. AUTOIMMUNITY 2021, 54(5):243–253.
Liu X, Li Q, Sun L, Chen L, Li Y, Huang B, Liu Y, Jiang C. miR-30e-5p regulates autophagy and apoptosis by targeting Beclin1 involved in contrast-induced acute kidney Injury. CURR MED CHEM. 2021;28(38):7974–84.
Xu J, Ma L, Fu P. MicroRNA-30c attenuates contrast-induced acute kidney injury by suppressing NLRP3 inflammasome. INT IMMUNOPHARMACOL. 2020;87:106457.
Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. MED RES REV. 2012;32(2):326–48.
Sun SQ, Zhang T, Ding D, Zhang WF, Wang XL, Sun Z, Hu LH, Qin SY, Shen LH, He B. Circulating MicroRNA-188, -30a, and– 30e as early biomarkers for contrast-Induced Acute kidney Injury. J AM HEART ASSOC 2016, 5(8).
Kodzwa R. ACR Manual on contrast media: 2018 updates. RADIOL TECHNOL. 2019;91(1):97–100.
Morabito S, Pistolesi V, Benedetti G, Di Roma A, Colantonio R, Mancone M, Sardella G, Cibelli L, Ambrosino M, Polistena F, et al. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. J NEPHROL. 2012;25(6):1098–107.
Wu MJ, Tsai SF, Lee CT, Wu CY. The predictive value of Hyperuricemia on Renal Outcome after contrast-enhanced computerized tomography. J CLIN MED 2019, 8(7).
Eng J, Wilson RF, Subramaniam RM, Zhang A, Suarez-Cuervo C, Turban S, Choi MJ, Sherrod C, Hutfless S, Iyoha EE, et al. Comparative effect of contrast media type on the incidence of contrast-Induced Nephropathy: a systematic review and Meta-analysis. ANN INTERN MED. 2016;164(6):417–24.
Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188(1):171–8.
Azzalini L, Poletti E, Lombardo F, Laricchia A, Beneduce A, Moscardelli S, Bellini B, Maccagni D, Cappelletti A, Ancona MB, et al. Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. INT J CARDIOL. 2019;290:59–63.
Balemans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzels JF. Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology. 2012;263(3):706–13.
Moore A, Dickerson E, Dillman JR, Vummidi D, Kershaw DB, Khalatbari S, Davenport MS. Incidence of nonconfounded post-computed tomography acute kidney injury in hospitalized patients with stable renal function receiving intravenous iodinated contrast material. CURR PROBL DIAGN RAD. 2014;43(5):237–41.
(2016) > Official release. Chinese Journal of Interventional Cardiology. 2016;24(06):315.
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, et al. Outcomes after angiography with sodium bicarbonate and Acetylcysteine. NEW ENGL J MED. 2018;378(7):603–14.
Biernacka-Fialkowska B, Szuksztul M, Suslik W, Dzierwa K, Tekieli L, Kostkiewicz M, Podolec P, Pieniazek P. Intravenous N-acetylcysteine for the PRevention of contrast-induced nephropathy – a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial. POSTEP KARDIOL INTER. 2018;14(1):59–66.
Kang X, Hu DY, Li CB, Ai ZS, Peng A. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail. 2015;37(10):297–303.
Palli E, Makris D, Papanikolaou J, Garoufalis G, Tsilioni I, Zygoulis P, Zakynthinos E. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study. CRIT CARE. 2017;21(1):269.
Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. AM J MED. 2014;127(10):987–1000.
Vanmassenhove J, Vanholder R, Lameire N. Statins for the prevention of contrast-induced acute kidney injury. CURR OPIN NEPHROL HY. 2016;25(6):508–17.
Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. AM J CARDIOL. 2014;114(4):541–8.
van Baar M, van Ruiten CC, Muskiet M, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41(8):1543–56.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. NAT REV CARDIOL. 2020;17(12):761–72.
Nusca A, Tuccinardi D, Pieralice S, Giannone S, Carpenito M, Monte L, Watanabe M, Cavallari I, Maddaloni E, Ussia GP, et al. Platelet effects of anti-diabetic therapies: New perspectives in the management of patients with diabetes and Cardiovascular Disease. FRONT PHARMACOL. 2021;12:670155.
Huang X, Guo X, Yan G, Zhang Y, Yao Y, Qiao Y, Wang D, Chen G, Zhang W, Tang C, et al. Dapagliflozin attenuates contrast-induced acute kidney Injury by regulating the HIF-1alpha/HE4/NF-kappaB pathway. J CARDIOVASC PHARM. 2022;79(6):904–13.
Kultursay B, Yilmaz C, Guven B, Mutlu D, Karagoz A. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI. KARDIOL POL. 2024;82(1):29–36.
Komiyama K, Ashikaga T, Inagaki D, Miyabe T, Arai M, Yoshida K, Miyazawa S, Nakada A, Kawamura I, Masuda S, et al. Sodium bicarbonate-ascorbic acid combination for Prevention of contrast-Induced Nephropathy in chronic kidney disease patients undergoing catheterization. CIRC J. 2017;81(2):235–40.
Xu Y, Zheng X, Liang B, Gao J, Gu Z. Vitamins for Prevention of contrast-induced acute kidney Injury: a systematic review and Trial Sequential Analysis. AM J CARDIOVASC DRUG. 2018;18(5):373–86.
Arabmomeni M, Najafian J, Abdar EM, Samadi M, Mirbagher L. Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy. ARYA ATHEROSCLER. 2015;11(1):43–9.
Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. AM J KIDNEY DIS. 2012;60(3):360–70.
Huber W, Huber T, Baum S, Franzen M, Schmidt C, Stadlbauer T, Beitz A, Schmid RM, Schmid S. Sodium bicarbonate prevents contrast-Induced Nephropathy in Addition to Theophylline: a Randomized Controlled Trial. Medicine. 2016;95(21):e3720.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03570-6